Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06122272
Other study ID # NELN202110A
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 19, 2023
Est. completion date December 2026

Study information

Verified date April 2024
Source Danone Nutricia
Contact Camille YU, PM
Phone 008618817338946
Email camille.yu@danone.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an exploratory study with the aim to gain insight and potentially generate hypotheses on health benefits of feeding with study product. This study explores in healthy subjects the effect of feeding with the test product compared to the control product in early life.


Description:

- Key exploratory objective is to find an effect on body composition. - Other exploratory objectives are to find an effect on growth parameters. - Safety and tolerance and the user experience will be investigated.


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date December 2026
Est. primary completion date September 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Months to 6 Months
Eligibility Inclusion Criteria: - Healthy, singleton, term born infants. - Infants aged 6 months(± 2 weeks) at enrolment. - Infants fed with formula (with or without additional weaning foods or drinks) before enrolment. - Written informed consent (IC) from parent(s) and/or legally acceptable representative(s) aged =18 years at enrolment. Exclusion Criteria: - Infants who require a special diet other than Formula with intact cow's milk protein. - Infants known or suspected to have cow's milk, fish protein, and/or soy allergy and/or lactose intolerance. - Infants with current or previous illnesses/conditions and/or known or suspected congenital diseases or malformations which could interfere with the study outcomes, as per investigator's clinical judgement. - Infants with previous, current, or intended participation in any other clinical study involving investigational or marketed products. - Incapability of infants' parents and/or legally acceptable representative(s) to comply with study protocol as per the judgement of the investigator or investigator's uncertainty about the willingness or ability of parents legally acceptable representative(s) to comply with the protocol requirements. - Employees and/or infants/family members or relatives of employees of Danone Nutricia, the participating sites, or any other nutrition company that develops Infant, Follow On or Young Child formulae.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Test Formula
The duration of the study for each subject from enrolment to final visit, is 12 months. Test Formula will be provided during this 12 month.
Control Formula
The duration of the study for each subject from enrolment to final visit, is 12 months. Control Formula will be provided during this 12 month.

Locations

Country Name City State
China The Hong Kong Polytechnic University Hong Kong Hong Kong
Hong Kong Hong Kong Center for Clinical Research Hong Kong

Sponsors (1)

Lead Sponsor Collaborator
Danone Nutricia

Countries where clinical trial is conducted

China,  Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Other Weight weight, unit: kg Every 6 months, up to 12 months
Other Length length, unit: cm Every 6 months, up to 12 months
Other BMI BMI = weight/length2, unit: kg/cm2 Every 6 months, up to 12 months
Other Product intake Study product intake: number of bottles and amount consumed per bottle Every 6 months, up to 12 months
Primary Body composition Fat mass (kg) Every 6 months, up to 12 months
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1